Search

Displaying results 1301 - 1310 of 2507 in total
  1. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3). It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transport...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  2. Drug

    Ribostamycin

    go.drugbank.com/drugs/DB03615
    ApprovedWithdrawn

    Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.

  3. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  4. Drug

    6-Deoxyerythronolide B

    go.drugbank.com/drugs/DB04070
    Experimental

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  5. Drug

    Hypoxanthine

    go.drugbank.com/drugs/DB04076
    Investigational

    Hypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  6. Drug

    9-Methylguanine

    go.drugbank.com/drugs/DB02489
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified i...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficienc...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying changes in body composition, neurops...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Elvitegravir

    go.drugbank.com/drugs/DB09101
    ApprovedInvestigational

    Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inducers